Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure

EE Egom, V Maher, Y El Hiani - International Journal of Cardiology, 2019 - Elsevier
Pulmonary hypertension (PH) due to left ventricular heart failure (LV-HF) is a disabling and
life-threatening disease for which there is currently no single marketed pharmacological …
被引用次数：12 相关文章

Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure.

EE Egom, V Maher, Y El Hiani - International Journal of Cardiology, 2018 - europepmc.org
Pulmonary hypertension (PH) due to left ventricular heart failure (LV-HF) is a disabling and
life-threatening disease for which there is currently no single marketed pharmacological …

Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure

EE Egom, V Maher, Y El Hiani - International …, 2019 - internationaljournalofcardiology.com
Pulmonary hypertension (PH) due to left ventricular heart failure (LV-HF) is a disabling and
life-threatening disease for which there is currently no single marketed pharmacological …

Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure

EE Egom, V Maher, Y El Hiani - International journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Pulmonary hypertension (PH) due to left ventricular heart failure (LV-HF) is a disabling and
life-threatening disease for which there is currently no single marketed pharmacological …